Hospital
Saint Peter's University Hospital
Saint Peter's University Hospital was paid $185.49M by Medicaid between Jan 2018 and Dec 2024, across 536 billing codes. Its largest line is 99283, emergency room visit (moderate) — 13% of everything it billed.
33Billing provider infoSAINT PETER'S UNIVERSITY HOSPITAL
NEW BRUNSWICK, NJ 08901
NEW BRUNSWICK, NJ 08901
33aNPI1114924834assigned 07/07/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$185.49M
24GClaims3,091,773
24DCodes billed536
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#8 of 93
Median peer was paid$30.60M
This provider vs. median6.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 354,479 | $27.41M | |
| 2019 | 345,326 | $27.56M | |
| 2020 | 276,805 | $20.24M | |
| 2021 | 382,959 | $25.30M | |
| 2022 | 620,253 | $29.11M | |
| 2023 | 617,340 | $29.30M | |
| 2024incomplete | 494,611 | $26.58M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 68,084 | 64,051 | $23.52M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.9% | 45,352 | 42,676 | $14.61M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.6% | 39,713 | 36,989 | $14.08M |
| G0378 | Hospital observation service, per hour | 6.6% | 12,421 | 10,909 | $12.17M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 5.1% | 26,484 | 2,686 | $9.45M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.2% | 142,034 | 123,046 | $5.93M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.9% | 80,309 | 75,968 | $5.29M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 2.4% | 30,946 | 29,159 | $4.41M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.8% | 4,528 | 4,272 | $3.40M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.8% | 10,895 | 10,186 | $3.27M |
| 59025 | Fetal non-stress test | 1.8% | 12,770 | 8,110 | $3.26M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.3% | 58,747 | 49,670 | $2.49M |
524 more codes
| 90834 | Psychotherapy session, about 45 minutes | 1.2% | 6,363 | $2.28M |
| 76819 | Fetal biophysical profile; without non-stress testing | 1.2% | 28,334 | $2.27M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.2% | 2,542 | $2.21M |
| OP710 | 1.2% | 16,131 | $2.17M | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.1% | 19,675 | $2.13M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.0% | 43,983 | $1.93M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.0% | 2,366 | $1.91M |
| 59050 | 1.0% | 7,439 | $1.88M | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 8,460 | $1.80M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,396 | $1.74M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 6,015 | $1.61M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 31,475 | $1.57M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 2,784 | $1.56M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 28,138 | $1.48M |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 4,016 | $1.43M |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 4,575 | $1.14M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 20,073 | $1.12M |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,208 | $1.07M |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 9,210 | $1.07M |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | <1% | 1,739 | $1.04M |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 7,132 | $1.02M |
| 92551 | <1% | 20,037 | $1.01M | |
| OP370 | <1% | 14,017 | $1000K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 5,147 | $978K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,001 | $962K |
| 76830 | Ultrasound, transvaginal | <1% | 5,208 | $949K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 65,848 | $939K |
| 99469 | Subsequent inpatient neonatal critical care, per day, 28 days or younger | <1% | 2,325 | $873K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 12,792 | $860K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 15,556 | $763K |
| 99480 | Subsequent intensive care, per day, low birth weight infant | <1% | 6,457 | $750K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 7,580 | $749K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,288 | $735K |
| OP272 | <1% | 18,056 | $728K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 27,175 | $713K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,073 | $680K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 8,730 | $679K |
| 99460 | <1% | 8,040 | $656K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 58,165 | $621K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 733 | $618K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 11,865 | $612K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,642 | $608K |
| 94060 | <1% | 5,076 | $605K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 17,450 | $582K |
| 99479 | Subsequent intensive care, per day, very low birth weight infant | <1% | 4,729 | $559K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,349 | $552K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,640 | $546K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 3,491 | $532K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 17,429 | $531K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 12,251 | $494K |
| 80053 | Comprehensive metabolic panel | <1% | 52,266 | $481K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,722 | $470K |
| 95812 | <1% | 868 | $462K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 19,549 | $456K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 26,483 | $446K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,720 | $436K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 10,078 | $428K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,082 | $425K |
| 97802 | <1% | 6,043 | $421K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 256 | $414K |
| 95782 | <1% | 506 | $380K | |
| 76813 | <1% | 4,019 | $378K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,303 | $372K |
| 97803 | <1% | 7,859 | $360K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 384 | $344K |
| 99173 | <1% | 22,822 | $339K | |
| 99205 | Prolong outpt/office vis | <1% | 2,257 | $332K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 2,236 | $331K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 846 | $326K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 4,156 | $325K |
| 99472 | Subsequent inpatient pediatric critical care, per day, 2-5 years | <1% | 830 | $319K |
| OP250 | <1% | 183,246 | $313K | |
| 93017 | <1% | 1,417 | $303K | |
| 81003 | <1% | 94,592 | $298K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,754 | $298K |
| 92579 | <1% | 2,117 | $297K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,086 | $296K |
| 92567 | <1% | 5,360 | $294K | |
| 76770 | <1% | 1,306 | $292K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,571 | $284K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,653 | $280K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,771 | $274K |
| 76536 | <1% | 1,150 | $270K | |
| 76825 | <1% | 885 | $269K | |
| 90651 | <1% | 1,818 | $267K | |
| 71045 | Radiologic examination, chest; single view | <1% | 11,491 | $266K |
| OP271 | <1% | 14,601 | $256K | |
| 92557 | <1% | 1,886 | $256K | |
| 97597 | <1% | 1,877 | $255K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 193 | $254K |
| 93325 | <1% | 1,031 | $252K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,414 | $249K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,191 | $248K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 482 | $237K |
| 95813 | <1% | 647 | $232K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,930 | $230K |
| OP270 | <1% | 9,472 | $228K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 3,899 | $222K |
| 94729 | <1% | 4,671 | $222K | |
| 92587 | <1% | 3,260 | $221K | |
| 76827 | <1% | 651 | $213K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 7,483 | $212K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,010 | $208K |
| 94727 | <1% | 4,407 | $206K | |
| 93970 | <1% | 1,625 | $203K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,437 | $194K |
| 76642 | <1% | 1,629 | $193K | |
| 90715 | <1% | 6,183 | $193K | |
| 99223 | Prolong inpt eval add15 m | <1% | 2,425 | $187K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 2,568 | $186K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 5,079 | $184K |
| 97161 | <1% | 2,905 | $180K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 144 | $177K |
| 99464 | <1% | 2,480 | $174K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 4,060 | $165K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,151 | $164K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 8,727 | $158K |
| 92526 | <1% | 3,098 | $153K | |
| 72082 | <1% | 1,640 | $151K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 3,010 | $149K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 1,551 | $147K |
| 73610 | <1% | 3,346 | $144K | |
| 99245 | <1% | 798 | $144K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,117 | $136K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,992 | $130K |
| 80320 | <1% | 5,495 | $130K | |
| 87590 | <1% | 6,785 | $128K | |
| 31575 | <1% | 513 | $128K | |
| 80329 | <1% | 3,089 | $127K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 387 | $126K |
| 73130 | <1% | 2,633 | $125K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 56,812 | $123K |
| 92588 | <1% | 1,575 | $122K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,510 | $121K |
| 73562 | <1% | 3,354 | $118K | |
| 90686 | <1% | 17,073 | $117K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 896 | $116K |
| 74018 | <1% | 5,313 | $115K | |
| 73110 | <1% | 2,379 | $114K | |
| 87490 | <1% | 6,793 | $106K | |
| 88341 | <1% | 2,016 | $106K | |
| 73630 | <1% | 3,151 | $106K | |
| 76820 | <1% | 1,405 | $103K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,167 | $102K |
| 77072 | <1% | 1,863 | $95K | |
| 73080 | <1% | 1,853 | $95K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 16,333 | $94K |
| 81025 | <1% | 30,805 | $94K | |
| 88304 | <1% | 2,097 | $91K | |
| 81329 | <1% | 862 | $90K | |
| 92582 | <1% | 682 | $86K | |
| 76870 | <1% | 406 | $85K | |
| 73090 | <1% | 1,555 | $79K | |
| 73030 | <1% | 1,821 | $79K | |
| 96415 | <1% | 670 | $79K | |
| 73590 | <1% | 1,561 | $78K | |
| 99201 | <1% | 1,810 | $76K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,148 | $75K |
| 82948 | <1% | 12,994 | $73K | |
| 87081 | <1% | 10,357 | $73K | |
| 99462 | <1% | 2,009 | $71K | |
| 95806 | <1% | 339 | $70K | |
| 84702 | <1% | 7,029 | $70K | |
| 77066 | Tomosynthesis, mammo | <1% | 579 | $70K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,340 | $69K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,020 | $68K |
| 88342 | <1% | 2,336 | $68K | |
| 95720 | <1% | 402 | $68K | |
| 84484 | <1% | 10,619 | $63K | |
| 70486 | <1% | 243 | $62K | |
| 73521 | <1% | 864 | $61K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,503 | $60K |
| 76801 | <1% | 401 | $55K | |
| 83690 | <1% | 11,045 | $54K | |
| 95951 | <1% | 190 | $53K | |
| 86885 | <1% | 8,157 | $53K | |
| 87040 | <1% | 4,971 | $53K | |
| 84144 | <1% | 3,472 | $52K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,999 | $49K |
| 73502 | <1% | 857 | $48K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 750 | $46K |
| 85610 | <1% | 10,051 | $45K | |
| OP278 | <1% | 473 | $45K | |
| 96376 | <1% | 2,344 | $45K | |
| 99177 | <1% | 1,075 | $44K | |
| 59514 | <1% | 62 | $44K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,380 | $44K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 33 | $43K |
| 71250 | <1% | 150 | $43K | |
| 85730 | <1% | 9,267 | $42K | |
| 84703 | <1% | 15,911 | $42K | |
| 86900 | <1% | 8,651 | $41K | |
| 69210 | <1% | 980 | $41K | |
| 01922 | <1% | 356 | $41K | |
| 94799 | <1% | 869 | $41K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,290 | $41K |
| 80061 | Lipid panel | <1% | 2,428 | $39K |
| 17250 | <1% | 389 | $38K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 143 | $37K |
| 72110 | <1% | 762 | $37K | |
| 81401 | <1% | 492 | $37K | |
| 90474 | <1% | 3,953 | $36K | |
| 86901 | <1% | 8,661 | $36K | |
| 90670 | <1% | 5,006 | $36K | |
| 90734 | <1% | 427 | $36K | |
| 85027 | <1% | 5,431 | $35K | |
| 96040 | <1% | 418 | $35K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,242 | $35K |
| 97162 | <1% | 610 | $35K | |
| 83735 | <1% | 8,812 | $32K | |
| 92550 | <1% | 1,197 | $32K | |
| 86580 | <1% | 2,577 | $31K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,307 | $31K |
| 86803 | <1% | 1,514 | $29K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,984 | $29K |
| 87186 | <1% | 3,802 | $29K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 858 | $29K |
| 77065 | Tomosynthesis, mammo | <1% | 290 | $29K |
| 84439 | <1% | 2,472 | $28K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 34 | $27K |
| 82397 | <1% | 1,740 | $27K | |
| J2704 | Injection, propofol, 10 mg | <1% | 9,737 | $27K |
| 0001A | <1% | 721 | $26K | |
| 86787 | <1% | 1,648 | $26K | |
| 0002A | <1% | 677 | $26K | |
| 99476 | <1% | 94 | $25K | |
| 88313 | <1% | 772 | $25K | |
| 70491 | <1% | 112 | $24K | |
| 95716 | <1% | 64 | $23K | |
| 3008F | <1% | 111,735 | $22K | |
| 72100 | <1% | 437 | $22K | |
| 54150 | <1% | 160 | $22K | |
| 92523 | <1% | 109 | $22K | |
| 73140 | <1% | 726 | $21K | |
| 92652 | <1% | 199 | $21K | |
| 76000 | <1% | 336 | $20K | |
| 82728 | <1% | 1,556 | $20K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 325 | $20K |
| 44970 | <1% | 15 | $19K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 552 | $19K |
| 85044 | <1% | 2,766 | $19K | |
| 0011A | <1% | 525 | $19K | |
| 82248 | <1% | 2,824 | $19K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 522 | $19K |
| 83880 | <1% | 1,313 | $19K | |
| 90656 | <1% | 1,640 | $19K | |
| 92555 | <1% | 464 | $18K | |
| 83020 | <1% | 1,729 | $18K | |
| 90662 | <1% | 1,028 | $18K | |
| 0012A | <1% | 496 | $18K | |
| 85652 | <1% | 2,775 | $18K | |
| 0071A | <1% | 482 | $18K | |
| 74019 | <1% | 467 | $17K | |
| 87340 | <1% | 2,220 | $17K | |
| 70496 | <1% | 25 | $17K | |
| 81015 | <1% | 13,486 | $17K | |
| 87420 | <1% | 2,165 | $17K | |
| 99243 | <1% | 241 | $16K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 19,779 | $16K |
| 0072A | <1% | 406 | $16K | |
| 93041 | <1% | 1,004 | $16K | |
| 99383 | <1% | 46 | $15K | |
| 90688 | <1% | 1,021 | $15K | |
| 96161 | <1% | 922 | $15K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 476 | $15K |
| 83605 | <1% | 2,276 | $15K | |
| 87400 | <1% | 6,479 | $15K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 5,008 | $15K |
| 86140 | <1% | 7,514 | $14K | |
| 43775 | <1% | 13 | $14K | |
| 86592 | <1% | 3,999 | $14K | |
| 93016 | <1% | 1,241 | $14K | |
| 90633 | <1% | 2,264 | $13K | |
| 43235 | <1% | 12 | $13K | |
| 77080 | <1% | 182 | $13K | |
| 85379 | <1% | 4,165 | $13K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,199 | $12K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 369 | $12K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 2,287 | $12K |
| 96127 | <1% | 5,991 | $12K | |
| 99151 | <1% | 705 | $12K | |
| 99152 | <1% | 1,294 | $12K | |
| 87481 | <1% | 204 | $12K | |
| 81513 | <1% | 104 | $11K | |
| 88720 | <1% | 2,933 | $11K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 9,752 | $11K |
| 73000 | <1% | 220 | $11K | |
| 86480 | <1% | 239 | $11K | |
| 97165 | <1% | 173 | $11K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,111 | $11K |
| J3490 | Unclassified drugs | <1% | 9,307 | $11K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,648 | $11K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,094 | $10K |
| 93018 | <1% | 1,240 | $10K | |
| 94726 | <1% | 259 | $10K | |
| 97116 | <1% | 256 | $10K | |
| 99471 | <1% | 12 | $10K | |
| 92522 | <1% | 124 | $10K | |
| 82105 | <1% | 670 | $9K | |
| 90620 | <1% | 103 | $9K | |
| 87077 | <1% | 1,925 | $9K | |
| 76775 | <1% | 68 | $9K | |
| 82550 | <1% | 2,966 | $9K | |
| 90746 | <1% | 176 | $9K | |
| 84156 | <1% | 1,671 | $8K | |
| 86762 | <1% | 1,665 | $8K | |
| 82570 | <1% | 1,961 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,882 | $8K |
| 73060 | <1% | 186 | $8K | |
| 12011 | <1% | 237 | $8K | |
| 99475 | <1% | 15 | $8K | |
| 84100 | <1% | 2,696 | $7K | |
| 88307 | <1% | 218 | $7K | |
| 94761 | <1% | 1,749 | $7K | |
| 88300 | <1% | 680 | $7K | |
| 87070 | <1% | 1,007 | $7K | |
| 29515 | <1% | 385 | $7K | |
| 92552 | <1% | 117 | $7K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,377 | $7K |
| 73100 | <1% | 158 | $7K | |
| 72158 | <1% | 15 | $7K | |
| 73552 | <1% | 113 | $7K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 115 | $7K |
| 82150 | <1% | 1,590 | $7K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,016 | $6K |
| 82950 | <1% | 1,445 | $6K | |
| 95251 | <1% | 315 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,832 | $6K |
| 88302 | <1% | 391 | $6K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,158 | $6K |
| 94760 | <1% | 271 | $6K | |
| 99219 | <1% | 60 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,762 | $6K |
| 95700 | <1% | 68 | $6K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 206 | $6K |
| 99443 | <1% | 332 | $6K | |
| 99217 | <1% | 12 | $5K | |
| 87205 | <1% | 1,392 | $5K | |
| 86336 | <1% | 121 | $5K | |
| C1769 | Guide wire | <1% | 383 | $5K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,556 | $5K |
| 0064A | <1% | 133 | $5K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 18 | $5K |
| 12001 | <1% | 148 | $5K | |
| 72131 | <1% | 25 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 98 | $4K |
| 99477 | <1% | 13 | $4K | |
| 90677 | <1% | 1,830 | $4K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,507 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 153 | $4K |
| 99384 | <1% | 12 | $4K | |
| 96401 | <1% | 65 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,157 | $4K |
| 90732 | <1% | 60 | $4K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 13 | $4K |
| 97164 | <1% | 63 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,091 | $4K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,161 | $3K |
| 92556 | <1% | 53 | $3K | |
| 82677 | <1% | 121 | $3K | |
| 83550 | <1% | 692 | $3K | |
| 96368 | <1% | 255 | $3K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 2,558 | $3K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 100 | $3K |
| 83540 | <1% | 738 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,425 | $3K |
| 90685 | <1% | 191 | $3K | |
| 72070 | <1% | 56 | $3K | |
| 90674 | <1% | 289 | $3K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 105 | $3K |
| 96367 | <1% | 202 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,052 | $3K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 964 | $3K |
| 87799 | <1% | 78 | $3K | |
| 99442 | <1% | 166 | $3K | |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | <1% | 61 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,876 | $2K |
| 29125 | <1% | 119 | $2K | |
| 84145 | <1% | 200 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,007 | $2K |
| 88738 | <1% | 565 | $2K | |
| 36430 | <1% | 38 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,350 | $2K |
| 99354 | <1% | 36 | $2K | |
| 1126F | <1% | 84,090 | $2K | |
| 29065 | <1% | 24 | $2K | |
| 76882 | <1% | 12 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 751 | $2K |
| 94664 | <1% | 13 | $2K | |
| 82951 | <1% | 179 | $2K | |
| 83615 | <1% | 351 | $2K | |
| 87512 | <1% | 79 | $2K | |
| 99497 | <1% | 83 | $2K | |
| 92585 | <1% | 54 | $2K | |
| 3078F | <1% | 62,674 | $2K | |
| 82553 | <1% | 251 | $1K | |
| 81002 | <1% | 1,557 | $1K | |
| 0054A | <1% | 40 | $1K | |
| 3074F | <1% | 58,721 | $1K | |
| 0073A | <1% | 82 | $1K | |
| 82607 | <1% | 147 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 744 | $1K |
| S9470 | Nutritional counseling, dietitian visit | <1% | 80 | $1K |
| OP258 | <1% | 1,367 | $1K | |
| 80076 | <1% | 202 | $1K | |
| 83655 | <1% | 97 | $1K | |
| 86308 | <1% | 176 | $1K | |
| 90473 | <1% | 93 | $1K | |
| 94618 | <1% | 13 | $1K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 12 | $1K |
| 88173 | <1% | 29 | $1K | |
| 87046 | <1% | 450 | $981.45 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 324 | $871.83 |
| 99218 | <1% | 18 | $838.22 | |
| 97014 | <1% | 34 | $813.78 | |
| 0013A | <1% | 22 | $720.00 | |
| 1159F | <1% | 64,089 | $719.00 | |
| 90480 | <1% | 65 | $680.00 | |
| 90723 | <1% | 6,290 | $675.31 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,319 | $609.95 |
| 82746 | <1% | 84 | $577.49 | |
| 0004A | <1% | 17 | $560.00 | |
| 87328 | <1% | 115 | $556.95 | |
| G9019 | Oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project) | <1% | 300 | $550.83 |
| 87329 | <1% | 116 | $540.14 | |
| 74022 | <1% | 12 | $520.77 | |
| 1160F | <1% | 57,209 | $519.00 | |
| 94762 | <1% | 16 | $514.80 | |
| 76821 | <1% | 20 | $513.54 | |
| 99441 | <1% | 52 | $480.29 | |
| 82803 | <1% | 76 | $472.76 | |
| 88172 | <1% | 14 | $452.91 | |
| 82805 | <1% | 12 | $403.86 | |
| 86923 | <1% | 31 | $398.03 | |
| 0081A | <1% | 50 | $360.00 | |
| 99000 | <1% | 15 | $288.08 | |
| 99292 | <1% | 12 | $281.43 | |
| 87075 | <1% | 27 | $278.38 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 25 | $264.87 |
| 82270 | <1% | 106 | $245.76 | |
| 82952 | <1% | 77 | $238.43 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 207 | $236.37 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 29 | $215.69 |
| C1776 | Joint device (implantable) | <1% | 45 | $200.28 |
| 82043 | <1% | 40 | $193.16 | |
| 82272 | <1% | 59 | $175.57 | |
| 91301 | <1% | 822 | $169.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 105 | $168.41 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 217 | $162.63 |
| 1036F | <1% | 70,441 | $150.00 | |
| 99417 | Prolong home eval add 15m | <1% | 25 | $148.77 |
| 92228 | <1% | 14 | $143.88 | |
| 91300 | <1% | 1,209 | $136.00 | |
| 91307 | <1% | 1,255 | $133.00 | |
| 99459 | <1% | 26 | $132.12 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 359 | $127.27 |
| 86706 | <1% | 15 | $122.31 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 261 | $118.91 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 337 | $114.24 |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | <1% | 309 | $110.14 |
| 81005 | <1% | 67 | $102.69 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 43 | $99.54 |
| 87210 | <1% | 92 | $94.43 | |
| 90647 | <1% | 4,030 | $90.30 | |
| C1729 | Catheter, drainage | <1% | 84 | $87.72 |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 85 | $82.07 |
| 3079F | <1% | 3,476 | $79.00 | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 14 | $77.23 |
| 84132 | <1% | 14 | $74.22 | |
| 90687 | <1% | 90 | $74.00 | |
| 96160 | <1% | 532 | $73.10 | |
| 36591 | <1% | 23 | $68.82 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 152 | $67.58 |
| 84550 | <1% | 15 | $65.42 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 84 | $63.19 |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 43 | $63.10 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 43 | $61.98 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 487 | $60.46 |
| 82784 | <1% | 14 | $54.24 | |
| 1125F | <1% | 2,369 | $52.00 | |
| 80354 | <1% | 14 | $51.79 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 18 | $49.19 |
| 0082A | <1% | 37 | $48.00 | |
| 3075F | <1% | 1,594 | $46.00 | |
| 90681 | <1% | 1,857 | $44.18 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 20 | $42.03 |
| 99001 | <1% | 12 | $40.28 | |
| 3077F | <1% | 2,135 | $38.00 | |
| 84436 | <1% | 12 | $31.92 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 60 | $30.57 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 16 | $30.00 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 13 | $25.80 |
| 91306 | <1% | 100 | $22.00 | |
| 85041 | <1% | 70 | $21.92 | |
| 99024 | <1% | 948 | $19.03 | |
| OP274 | <1% | 16 | $17.65 | |
| 99408 | <1% | 15 | $17.39 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 72 | $17.25 |
| 82009 | <1% | 17 | $16.11 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 66 | $14.53 |
| J0706 | Injection, caffeine citrate, 5 mg | <1% | 13 | $13.81 |
| 90716 | <1% | 286 | $13.06 | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 73 | $11.00 |
| 90707 | <1% | 297 | $10.07 | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 15 | $6.00 |
| 91321 | <1% | 14 | $5.09 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 29 | $5.00 |
| 3080F | <1% | 199 | $5.00 | |
| 91308 | <1% | 108 | $4.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 19 | $3.29 |
| 90700 | <1% | 168 | $3.02 | |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 13 | $2.28 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 28 | $2.00 |
| 90710 | <1% | 12 | $1.00 | |
| 91305 | <1% | 112 | $1.00 | |
| 90661 | <1% | 394 | $0.50 | |
| 90697 | <1% | 31 | $0.12 | |
| 90658 | <1% | 304 | $0.05 | |
| 3725F | 0% | 11,393 | $0.00 | |
| 3016F | 0% | 3,119 | $0.00 | |
| 3288F | 0% | 16 | $0.00 | |
| 1034F | 0% | 333 | $0.00 | |
| 90619 | 0% | 67 | $0.00 | |
| 90696 | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTOLDT, GARRICK (CFO)
Parent organizationSAINT PETER'S HEALTHCARE SYSTEM, INC.
| Provider | Location | Paid |
|---|---|---|
| Saint Peter's Healthcare System Physician Associates | New Brunswick, NJ | $1.30M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.